{
    "nct_id": "NCT02684058",
    "official_title": "Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)",
    "inclusion_criteria": "* Diagnosis of BRAF V600 mutant High Grade glioma that had relapsed, progressed or failed to respond to frontline therapy\n* Diagnosis of BRAF V600 mutant Low Grade glioma with progressive disease following surgical excision, or non-surgical candidates with necessity to begin first systemic treatment because of a risk of neurological impairment with progression.\n* Confirmed measurable disease\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 12 Months\nMust have maximum age of 17 Years",
    "exclusion_criteria": "* Previous treatment with dabrafenib, trametinib, other RAF inhibitor, other MEK or ERK inhibitor\n* HGG patient: Cancer treatment within the past 3 weeks. LGG patient: Any systemic therapy or radiotherapy prior to enrollment\n* LGG patients: history of allergic reaction or contraindications to the use of carboplatin or vincristine\n* Stem cell transplant within the past 3 months\n* History of heart disease\n* Pregnant or lactating females",
    "miscellaneous_criteria": "Key"
}